Management of abnormal uterine bleeding in adolescents.
Wilkinson
Jeffrey P
JP
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, USA. Jeffrey.Wilkinson@duke.edu
Kadir
Rezan A
RA
D000293:Adolescent; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D002404:Catheterization; D002648:Child; D015942:Factor VIIa / Q000627:therapeutic use; D005260:Female; D006474:Hemorrhagic Disorders / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D006490:Hemostatics / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008595:Menorrhagia / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D017713:Platelet Transfusion; D011994:Recombinant Proteins / Q000627:therapeutic use; D055357:Uterine Artery Embolization; D014592:Uterine Hemorrhage / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D055815:Young Adult
D000933:Antifibrinolytic Agents; D006490:Hemostatics; D006728:Hormones; D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa